Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma

Journal of Clinical Oncology

Volumn 34, Issue 15, 2016, Pages 1757-1763

  Korfel, Agnieszka ^a   Schlegel, Uwe ^b   Herrlinger, Ulrich ^c   Dreyling, Martin ^d   Schmidt, Christian ^d   Von Baumgarten, Luisa ^d   Pezzutto, Antonio ^a   Grobosch, Thomas ^a   Kebir, Sied ^c   Thiel, Eckhard ^a   Martus, Peter ^e   Kiewe, Philipp ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CLEMASTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TEMOZOLOMIDE; TEMSIROLIMUS; THIOTEPA; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ATRIAL FIBRILLATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BRAIN HISTOLOGY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REDUCTION; DRUG FEVER; DRUG MEGADOSE; DRUG PENETRATION; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; IMMUNOCOMPROMISED PATIENT; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEUKOPENIA; MALE; MULTICENTER STUDY; NEUROTOXICITY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SEIZURE; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; ANALOGS AND DERIVATIVES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; SIROLIMUS;

EID: 84969584687     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.9897     Document Type: Conference Paper

References (33)

1. Citterio G, Reni M, Ferreri AJ: Present and future treatment options for primary CNS lymphoma. Expert Opin Pharmacother 16:2569-2579, 2015
2. Hottinger AF, DeAngelis LM, Yahalom J, et al: Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69: 1178-1182, 2007
3. Nguyen PL, Chakravarti A, Finkelstein DM, et al: Results of whole brain radiation as salvage of methotrexate failure for immunocompetent patients with primary central nervous system lymphoma. J Clin Oncol 23:1507-1513, 2005
4. Herrlinger U, Küker W, Uhl M, et al: NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report. Ann Neurol 57:843-847, 2005
5. Omuro AM, Ben-Porat LS, Panageas KS, et al: Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595-1600, 2005
6. Fischer L, Thiel E, Klasen HA, et al: Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141-1145, 2006
7. Voloschin AD, Betensky R, Wen PY, et al: Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 86:211-215, 2008
8. Batchelor TT, Grossman SA, Mikkelsen T, et al: Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76: 929-930, 2011
9. Reni M, Zaja F, Mason W, et al: Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96:864-867, 2007
10. Enting RH, Demopoulos A, DeAngelis LM, et al: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901-903, 2004
11. Nayak L, Abrey LE, Drappatz J, et al: Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma 54:58-61, 2013
12. Arellano-Rodrigo E, López-Guillermo A, Bessell EM, et al: Salvage treatment with etoposide (VP- 16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70:219-224, 2003
13. Tyson RM, Siegal T, Doolittle ND, et al: Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 44: 627-633, 2003
14. Mappa S, Marturano E, Licata G, et al: Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol 31:143-150, 2013
15. Maza S, Kiewe P, Munz DL, et al: First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro-oncol 11:423-429, 2009
16. Plotkin SR, Betensky RA, Hochberg FH, et al: Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10:5643-5646, 2004
17. Soussain C, Choquet S, Fourme E, et al: Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stemcell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: A retrospective study of 79 cases. Haematologica 97:1751-1756, 2012
18. Fingar DC, Blenis J: Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171, 2004
19. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractorymantle cell lymphoma. J Clin Oncol 27:3822-3829, 2009
20. Witzig TE, Reeder CB, LaPlant BR, et al: A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25: 341-347, 2011
21. Smith SM, van Besien K, Karrison T, et al: Temsirolimus has activity in non-mantle cell non- Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 28: 4740-4746, 2010
22. Kuhn JG, Chang SM, Wen PY, et al: Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13:7401-7406, 2007
23. Abrey LE, Batchelor TT, Ferreri AJ, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005
24. Simon R: How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079-1085, 1987
25. Collett D: Modelling survival data, in Medical Research (ed 2). Boca Raton, FL, Chapman and Hall, 2003, pp 35-37
26. Abrey LE, Ben-Porat L, Panageas KS, et al: Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711-5715, 2006
27. Witzens-Harig M, Memmer ML, Dreyling M, et al: A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor temsirolimus added to standard therapy of rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-cell lymphoma - the STORM trial. BMC Cancer 13: 308, 2013
28. Hess G, Keller U, Scholz CW, et al: Safety and efficacy of temsirolimus in combination with bendamustine and rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 29:1695-1701, 2015
29. Ansell SM, Tang H, Kurtin PJ, et al: Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study. Lancet Oncol 12:361-368, 2011
30. Teachey DT, Sheen C, Hall J, et al: mTOR inhibitors are synergistic with methotrexate: An effective combination to treat acute lymphoblastic leukemia. Blood 112:2020-2023, 2008
31. Ponzoni M, Issa S, Batchelor TT, et al: Beyond high-dose methotrexate and brain radiotherapy: Novel targets and agents for primary CNS lymphoma. Ann Oncol 25:316-322, 2014
32. Wilson WH, Young RM, Schmitz R, et al: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922-926, 2015
33. Donelli MG, Zucchetti M, D'Incalci M: Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251-260, 1992